Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.